Gene G Kinney from Boca Raton, FL, age 56

Us Patents

3-Fluoro-2-Oxindole Modulators Of Kcnq Potassium Channels And Use Thereof In Treating Migraine And Mechanistically Related Disease
view source
US Patent:

6855829, Feb 15, 2005
Filed:

Feb 14, 2002
Appl. No.:

10/075703
Inventors:

Steven I. Dworetzky - Middlefield CT, US
Valentin K. Gribkoff - Wallingford CT, US
Gene G. Kinney - Collegeville PA, US
Piyasena Hewawasam - Middletown CT, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07D209/34
US Classification:

548486, 514416
Abstract:

Compounds which function as modulators, particularly, openers, of human KCNQ potassium channel proteins or polypeptides, particularly, central nervous system (CNS)-located KCNQ potassium channels, and heteromultimers thereof, and their use in the treatment of migraine are provided by the present invention. One novel type of potassium channel polypeptide openers provided by the present invention is the fluorooxindole compounds, described for the first time as therapeutics for the treatment of migraine by preventing the asynchronous firing of neurons. Other KCNQ potassium channel opener compounds that are also useful in the treatments of the invention include 2,4-disubstituted pyrimidine-5-carboxamide derivatives. One or more of the compounds according to the present invention may be utilized alone, in combination, or in conjunction with other treatment modalities for reducing, ameliorating and/or alleviating migraine or diseases similar to, or mechanistically related to, migraine, e. g. , cluster headache.

Anti-Addl Monoclonal Antibody And Use Thereof
view source
US Patent:

7731962, Jun 8, 2010
Filed:

Oct 17, 2006
Appl. No.:

11/581843
Inventors:

Gene Kinney - Collegeville PA, US
William R. Strohl - Bridgewater NJ, US
Zhiqiang An - Ambler PA, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 435 72
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

7780963, Aug 24, 2010
Filed:

Oct 21, 2005
Appl. No.:

11/256332
Inventors:

Paul Acton - Quakertown PA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Lei Chang - Westmont IL, US
Elizabeth Chen Dodson - Souderton PA, US
Gene Kinney - Collegeville PA, US
William Klein - Winetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kirsten Viola - Chicago IL, US
Assignee:

Merck & Co., Inc. - Rahway NJ
Northwestern University - Evanston IL
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β1-42.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

7811563, Oct 12, 2010
Filed:

Oct 21, 2005
Appl. No.:

11/577426
Inventors:

Paul Acton - Quakertown PA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Elizabeth Chen Dodson - Souderton PA, US
Gene Kinney - Collegeville PA, US
William L Klein - Winetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kirsten Viola - Chicago IL, US
Lei Chang - Westmont IL, US
Assignee:

Northwestern University - Evanston IL
Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Peptide Conjugate Compositions And Methods For The Prevention And Treatment Of Alzheimer's Disease
view source
US Patent:

7850973, Dec 14, 2010
Filed:

May 1, 2006
Appl. No.:

11/919897
Inventors:

Victor M. Garsky - Blue Bell PA, US
Joseph G. Joyce - Lansdale PA, US
Paul M. Keller - Lansdale PA, US
Gene Kinney - Collegeville PA, US
Xiaoping Liang - Collegeville PA, US
John W. Shiver - Doylestown PA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/00
A61K 39/08
A61K 39/095
A61K 39/02
A61K 38/08
A61K 45/00
A61K 33/06
US Classification:

4241851, 42419711, 4242361, 4242471, 4242501, 4241821, 424682, 424698, 4242781, 4242821, 4242831
Abstract:

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

Anti-Addl Monoclonal Antibody And Use Thereof
view source
US Patent:

8105593, Jan 31, 2012
Filed:

Jun 4, 2010
Appl. No.:

12/793775
Inventors:

Gene Kinney - Collegeville PA, US
William R. Strohl - Bridgewater NJ, US
Zhiqiang An - Ambler PA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 5303881, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

8128930, Mar 6, 2012
Filed:

Jul 1, 2010
Appl. No.:

12/828411
Inventors:

Paul Acton - Newbury Park CA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Lei Chang - Westmont IL, US
Elizabeth Chen Dodson - Soudertown PA, US
Gene Kinney - Collegeville PA, US
William L. Klein - Winnetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kristen Viola - Chicago IL, US
Assignee:

Northwestern University - Evanston IL
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 5303881, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

8383113, Feb 26, 2013
Filed:

Feb 8, 2012
Appl. No.:

13/368742
Inventors:

Paul Acton - Quakertown PA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Lei Chang - Westmont IL, US
Elizabeth Chen Dodson - Souderton PA, US
Gene Kinney - Collegeville PA, US
William Klein - Winetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kristen Viola - Chicago IL, US
Assignee:

Northwestern University - Evanston IL
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 5303881, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.